vincaleukoblastine and Glioblastoma

vincaleukoblastine has been researched along with Glioblastoma* in 1 studies

Other Studies

1 other study(ies) available for vincaleukoblastine and Glioblastoma

Article	Year
Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma. Journal of medicinal chemistry, 2017, 03-09, Volume: 60, Issue:5 The DYRK family contains kinases that are up-regulated in malignancy and control several cancer hallmarks. To assess the anticancer potential of inhibitors targeting DYRK kinases, we developed a series of novel DYRK inhibitors based on the 7-azaindole scaffold. All compounds were tested for their ability to inhibit DYRK1A, DYRK1B, DYRK2, and the structurally related CLK1. The library was screened for anticancer efficacy in established and stem cell-like glioblastoma cell lines. The most potent inhibitors (IC Topics: Brain Neoplasms; Glioblastoma; Humans; Phosphorylation; Protein Kinases; Structure-Activity Relationship; Tyrosine	2017

Article

Year

Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma.

Journal of medicinal chemistry, 2017, 03-09, Volume: 60, Issue:5

The DYRK family contains kinases that are up-regulated in malignancy and control several cancer hallmarks. To assess the anticancer potential of inhibitors targeting DYRK kinases, we developed a series of novel DYRK inhibitors based on the 7-azaindole scaffold. All compounds were tested for their ability to inhibit DYRK1A, DYRK1B, DYRK2, and the structurally related CLK1. The library was screened for anticancer efficacy in established and stem cell-like glioblastoma cell lines. The most potent inhibitors (IC

Topics: Brain Neoplasms; Glioblastoma; Humans; Phosphorylation; Protein Kinases; Structure-Activity Relationship; Tyrosine

2017